Vera Therapeutics, Inc. announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. Mr. Johnson brings more than 30 years of commercialization and operational experience in the biopharmaceutical industry. Prior to joining Vera, he served as the Chief Commercial Officer at Global Blood Therapeutics (GBT) until it was acquired by Pfizer in 2022, during which time he established the company?s global commercial functions and led the launch of Oxbryta.

Prior to GBT, Mr. Johnson spent 15 years at Gilead Sciences, Inc., in roles of increasing responsibility. His most recent position was as Vice President of Sales and Marketing for Gilead?s Liver Disease Business Unit, where he was responsible for building and leading the company?s liver disease franchises, including commercially launching four industry leading medicines to treat hepatitis. Prior to that position, he was Vice President of Sales and Marketing for Gilead?s Antiviral Business Unit, where he helped launch and oversee the HIV franchise.

Mr. Johnson previously had an 11-year tenure at GSK plc, where he held various positions in sales, product marketing, business development, global commercial strategy and portfolio development. Mr. Johnson currently serves on the board of directors of Caribou Biosciences, a public gene therapy company. He received a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.